Pseudobulbar Affect (PBA)

What is Pseudobulbar affect?

Pseudobulbar affect (PBA) is a neurological condition characterized by sudden, involuntary episodes of laughing or crying that are disproportionate or unrelated to the person’s actual emotional state. Unlike ordinary mood swings, these emotional outbursts are triggered by minimal stimuli, can last from a few seconds to several minutes, and often feel embarrassing or socially disabling. PBA is sometimes referred to as “emotional incontinence” because the individual cannot control the flow of emotions.

PBA occurs when the brain pathways that normally regulate emotional expression are disrupted. The most common mechanism involves damage to the corticobulbar tract—a set of nerve fibers that connect the cerebral cortex (the brain’s “thinking” region) with the brainstem areas that control facial muscles and vocalization. When this circuit is impaired, the “brake” on emotional expression is lost, resulting in exaggerated laughter or crying. The condition can affect people of any age but is most frequently seen in adults with underlying neuro‑degenerative diseases.

Key points

• Sudden, involuntary laughter or crying.
• Emotional response is out of proportion to the situation.
• Episodes are brief (seconds to minutes) but may occur many times per day.
• Not a mood disorder (e.g., depression) and does not reflect the person’s true feelings.

Common Causes

Damage to the neural networks that control emotional expression can arise from a variety of medical conditions. The following disorders are most frequently associated with PBA:

• Multiple Sclerosis (MS) – demyelination of brainstem pathways.
• Amyotrophic Lateral Sclerosis (ALS) – degeneration of motor neurons that includes corticobulbar tracts.
• Traumatic Brain Injury (TBI) – especially injuries involving the frontal lobes or brainstem.
• Stroke – ischemic or hemorrhagic lesions in the cerebellum, brainstem, or cortical areas.
• Alzheimer’s disease and other dementias – progressive loss of cortical networks.
• Parkinson’s disease – involvement of basal ganglia and brainstem circuitry.
• Brain tumors – particularly those in the frontal or temporal lobes.
• Progressive Supranuclear Palsy (PSP) – a rare neurodegenerative disorder.
• Guillain‑Barré syndrome (rare) – can involve brainstem cranial nerves.
• Infectious encephalitis – inflammation of brain tissue may disrupt emotional pathways.

Associated Symptoms

Because PBA results from underlying brain injury, it is often accompanied by other neurological signs.

• Muscle weakness or spasticity (common in ALS or MS).
• Difficulty with speech (dysarthria) or swallowing (dysphagia).
• Cognitive changes such as memory problems, slowed thinking, or confusion.
• Balance problems, gait instability, or coordination deficits.
• Headaches or visual disturbances when a tumor or stroke is the cause.
• Fatigue and sleep disturbances, frequently reported in MS and dementia.
• Emotional symptoms that may be mistaken for depression or anxiety (e.g., tearfulness, social withdrawal).

When to See a Doctor

The presence of PBA itself warrants medical evaluation, but certain situations require prompt attention:

• Episodes of laughing or crying are frequent (more than a few times per day) and interfere with work, school, or relationships.
• New onset of emotional outbursts after a head injury, stroke, or diagnosis of a neurological disease.
• Accompanying neurological symptoms such as sudden weakness, numbness, slurred speech, or loss of coordination.
• Signs of depression, suicidal thoughts, or severe anxiety that develop alongside PBA.
• Any sudden change in mental status, such as confusion or inability to stay awake.

Early evaluation helps differentiate PBA from mood disorders and guides appropriate treatment.

Diagnosis

There is no laboratory test that directly confirms PBA, so clinicians rely on a thorough history, physical exam, and standardized questionnaires.

1. Clinical Interview

• Detailed description of emotional episodes (duration, triggers, frequency).
• Review of underlying neurological conditions, recent head trauma, or medication changes.

2. Neurological Examination

• Assessment of cranial nerve function, motor strength, reflexes, coordination, and gait.
• Evaluation for signs of brainstem or corticobulbar tract involvement.

3. Screening Tools

• Center for Neurologic Study–Lability Scale (CNS‑LS) – a 7‑item questionnaire that quantifies frequency and severity of episodes. A score ≥13 suggests PBA.
• Pathological Laughter and Crying Scale (PLACS) – used in research settings.

4. Imaging & Other Tests (to identify cause)

• MRI of the brain – detects demyelination, stroke, tumor, or atrophy.
• CT scan – useful in emergency settings for acute hemorrhage.
• Blood work (CBC, metabolic panel, inflammatory markers) – rules out infections or metabolic disturbances.
• Electroencephalogram (EEG) if seizures are suspected.

Diagnosis is confirmed when the emotional outbursts are disproportionate, involuntary, and occur in the context of a known neurological disorder, with other causes (e.g., depression, medication side‑effects) excluded.

Treatment Options

Management of PBA focuses on two areas: treating the underlying brain condition and reducing the frequency/intensity of emotional outbursts.

Medication

• Dextromethorphan/quinidine (Nuedexta™) – the only FDA‑approved combination for PBA. Dextromethorphan modulates glutamate signaling; quinidine inhibits its metabolism, increasing blood levels. Clinical trials show a 50‑60 % reduction in episode frequency (FDA, 2010).
• Selective serotonin reuptake inhibitors (SSRIs) – sertraline, fluoxetine, and citalopram have off‑label benefit, particularly when PBA coexists with depression.
• Tricyclic antidepressants (TCAs) – amitriptyline or nortriptyline can be used, but side‑effects limit use in older adults.
• Anticonvulsants – gabapentin or pregabalin have anecdotal support for reducing emotional lability.

Non‑pharmacologic Strategies

• Education & counseling – teaching patients and families that PBA is a neurological symptom reduces stigma and improves coping.
• Behavioral techniques – paced breathing, distraction, and “response‑blocking” (consciously pausing before reacting) can lessen episode severity.
• Speech‑language therapy – especially in ALS or MS, helps maintain communication skills despite emotional outbursts.
• Support groups – sharing experiences with peers can alleviate isolation.

Addressing the Underlying Condition

Optimizing treatment for the primary disease (e.g., disease‑modifying therapy for MS, disease‑specific meds for Parkinson’s, rehabilitation after stroke) can indirectly reduce PBA frequency.

Follow‑up Care

Regular appointments (every 3–6 months) allow dose adjustments, monitoring of side‑effects, and reassessment of functional impact.

Prevention Tips

While PBA cannot always be prevented, certain measures may lower risk or lessen severity:

• Control vascular risk factors – hypertension, diabetes, high cholesterol, and smoking increase stroke risk, a major trigger for PBA.
• Use protective equipment – helmets and seat belts reduce the likelihood of traumatic brain injury.
• Adhere to disease‑modifying therapies for MS, ALS, or Parkinson’s to slow neurodegeneration.
• Prompt treatment of infections that could cause encephalitis or meningitis.
• Regular neurological follow‑up – early detection of new lesions or disease progression allows timely intervention.
• Medication review – some drugs (e.g., certain antipsychotics) can exacerbate emotional lability; discuss all meds with a pharmacist or neurologist.

Emergency Warning Signs

Key Takeaways

Pseudobulbar affect is a treatable neurological condition that can significantly impact quality of life. Recognizing its characteristic involuntary laughing or crying, understanding the common underlying causes, and seeking timely evaluation are crucial. With FDA‑approved medication, supportive therapies, and management of the primary brain disorder, most patients achieve marked improvement and regain confidence in social and professional settings.

References:

• Mayo Clinic. “Pseudobulbar affect.” Updated 2023. https://www.mayoclinic.org
• National Institute of Neurological Disorders and Stroke (NINDS). “Pseudobulbar Affect Information Page.” 2022.
• FDA. “Nuedexta (dextromethorphan/quinidine) prescribing information.” 2010.
• Cleveland Clinic. “Pseudobulbar affect (Emotional Incontinence).” 2024.
• World Health Organization. “Stroke Fact Sheet.” 2022.